ArticleGut2021
Loss of hepatic Mboat7 leads to liver fibrosis.
Open access · bronzeAbstract readMulticenter Study
In one paragraph
Article in Gut, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers.
0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed
11.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 117 citations in OpenAlex.
- Ultra-rapid progression of MAFLD to cirrhosis and post-transplant steatosis in a patient with a polygenic risk profile.MedScience · 2026Article
- Waist-to-height ratio as a practical indicator for screening pediatric metabolic dysfunction-associated steatotic liver disease in diverse populations and genetic backgrounds.World journal of pediatrics : WJP · 2026Article
- Genetic and lifestyle determinants of lipid profiles in Japanese young adults: evidence from MBOAT7 rs641738.Lipids in health and disease · 2026Article
- Mechanisms and therapeutic insights into MASH-associated fibrosis.Trends in endocrinology and metabolism: TEM · 2026Review
- Targeting the LPI/GPR55 Axis in MAFLD and MASH: Novel Insights, Therapeutic Strategies and Future Directions.Liver international : official journal of the International Association for the Study of the Liver · 2026Review
- CD36-PPARγ-SPP1 axis mediates hepatocyte-macrophage coordination to drive MASLD-related liver fibrosis.JHEP reports : innovation in hepatology · 2026Article
- Metabolic dysfunction-associated steatotic liver disease and steatohepatitis-associated hepatocarcinoma preclinical models.Nature reviews. Gastroenterology & hepatology · 2026Review
- Hepatotoxicity Prediction and Multi-omics Reveal Mitochondrial and Lipid Metabolic Dysregulation in PMEnvironment & health (Washington, D.C.) · 2026Article
- TMEM39A acts as a novel profibrotic factor to activate hepatic stellate cells partially via the cell adhesion molecule signaling axis.Frontiers in cell and developmental biology · 2026Article
- Rethinking the hepatoprotective potential of vegetarian diets in dysfunction-associated steatotic liver disease/metabolic-associated fatty liver disease: a critical narrative review.Frontiers in nutrition · 2026Review
- [Analysis of serum lipidomics for a spontaneous hepatic fibrosis mouse model].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025Article
- Physiological roles of phosphoinositides and inositol phosphates: Implications for metabolic dysfunction-associated steatotic liver disease.Clinical science (London, England : 1979) · 2025Review
- Hepatic ASPG-mediated lysophosphatidylinositol catabolism impairs insulin signal transduction.The EMBO journal · 2025Article
- The current findings on the gut-liver axis and the molecular basis of NAFLD/NASH associated with gut microbiome dysbiosis.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Gene-based therapies for steatotic liver disease.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Review
- Unraveling Metabolic Dysfunction-Associated Steatotic Liver Disease Through the Use of Omics Technologies.International journal of molecular sciences · 2025Review
- Metabolic and genetic mechanisms of metabolic dysfunction-associated steatotic liver disease: an integrative perspective from molecular pathways to clinical challenges.Frontiers in endocrinology · 2025Review
- Role of genetic variants and DNA methylation of lipid metabolism-related genes in metabolic dysfunction-associated steatotic liver disease.Frontiers in physiology · 2025Review
- Impact of genotyping (Frontiers in endocrinology · 2025Article
- Immunological dynamics in MASH: from landscape analysis to therapeutic intervention.Journal of gastroenterology · 2024Review
10 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
32 authors at 12 institutions in 3 countries.
Veera Raghavan ThangapandiDepartment of Medicine I, University Hospital Dresden, Technische Universität (TU) Dresden, Dresden, Sachsen, Germany.
Oskar KnittelfelderMax-Planck-Institute of Molecular Cell Biology and Genetics, Dresden, Sachsen, Germany.ORCID 0000-0002-1565-7238
Mario BroschDepartment of Medicine I, University Hospital Dresden, Technische Universität (TU) Dresden, Dresden, Sachsen, Germany.
Eleonora PatsenkerDepartment of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland.
Olga VvedenskayaMax-Planck-Institute of Molecular Cell Biology and Genetics, Dresden, Sachsen, Germany.
Stephan BuchDepartment of Medicine I, University Hospital Dresden, Technische Universität (TU) Dresden, Dresden, Sachsen, Germany.
Sebastian HinzDepartment of Visceral and Thoracic Surgery, Universitatsklinikum Schleswig-Holstein, Kiel, Schleswig-Holstein, Germany.
Alexander HendricksDepartment of Visceral and Thoracic Surgery, Universitatsklinikum Schleswig-Holstein, Kiel, Schleswig-Holstein, Germany.ORCID 0000-0002-7286-9245
Marina NatiInstitute for Clinical Chemistry and Laboratory Medicine, University Hospital Dresden, Technische Universität (TU) Dresden, Dresden, Sachsen, Germany.
Alexander HerrmannDepartment of Medicine I, University Hospital Dresden, Technische Universität (TU) Dresden, Dresden, Sachsen, Germany.
Devavrat Ravindra RekhadeDepartment of Medicine I, University Hospital Dresden, Technische Universität (TU) Dresden, Dresden, Sachsen, Germany.
Thomas BergDivision of Hepatology, Department of Oncology, Gastroenterology, Hepatology Pulmonology, and Infectious Diseases, University Hospital Leipzig, Leipzig, Sachsen, Germany.
Madlen Matz-SojaDivision of Hepatology, Department of Oncology, Gastroenterology, Hepatology Pulmonology, and Infectious Diseases, University Hospital Leipzig, Leipzig, Sachsen, Germany.
Klaus HuseLeibniz Institute for Age Research Fritz-Lipmann Institute, Jena, Thüringen, Germany.
Edda KlippDepartment of Theoretical Biophysics, Institute of Biology, Humboldt-Universität zu Berlin, Berlin, Germany.
Josch K PaulingDepartment of Theoretical Biophysics, Institute of Biology, Humboldt-Universität zu Berlin, Berlin, Germany.
Judith Ah WodkeDepartment of Theoretical Biophysics, Institute of Biology, Humboldt-Universität zu Berlin, Berlin, Germany.
Jacobo Miranda AckermanMax-Planck-Institute of Molecular Cell Biology and Genetics, Dresden, Sachsen, Germany.
Malte von BoninDepartment of Medicine I, University Hospital Dresden, Technische Universität (TU) Dresden, Dresden, Sachsen, Germany.
Elmar AignerDepartment of Medicine, Paracelsus Medical University Salzburg, Salzburg, Austria.
Christian DatzDepartment of Internal Medicine, Hospital Oberndorf, Teaching Hospital of the Paracelsus Private University of Salzburg, Obendorf, Austria.ORCID 0000-0001-7838-4532
Witigo von SchönfelsDepartment of Visceral and Thoracic Surgery, Universitatsklinikum Schleswig-Holstein, Kiel, Schleswig-Holstein, Germany.
Sophie NehringDepartment of Medicine I, University Hospital Dresden, Technische Universität (TU) Dresden, Dresden, Sachsen, Germany.
Sebastian ZeissigDepartment of Medicine I, University Hospital Dresden, Technische Universität (TU) Dresden, Dresden, Sachsen, Germany.
Christoph RöckenDepartment of Pathology, University Hospital Schleswig Holstein, Kiel, Schleswig-Holstein, Germany.ORCID 0000-0002-6989-8002
Andreas DahlCenter for Regenerative Therapies Dresden (CRTD), Technische Universität (TU) Dresden, Dresden, Germany.
Triantafyllos ChavakisMax-Planck-Institute of Molecular Cell Biology and Genetics, Dresden, Sachsen, Germany.
Felix StickelDepartment of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland.
Andrej ShevchenkoMax-Planck-Institute of Molecular Cell Biology and Genetics, Dresden, Sachsen, Germany.ORCID 0000-0002-5079-1109
Clemens SchafmayerDepartment of General, Visceral, Vascular and Transplantation Surgery, University of Rostock, Rostock, Mecklenburg-Vorpommern, Germany.
Jochen HampeDepartment of Medicine I, University Hospital Dresden, Technische Universität (TU) Dresden, Dresden, Sachsen, Germany jochen.hampe@uniklinikum-dresden.de.ORCID 0000-0002-2421-6127
Pallavi SubramanianInstitute for Clinical Chemistry and Laboratory Medicine, University Hospital Dresden, Technische Universität (TU) Dresden, Dresden, Sachsen, Germany.
Technische Universität Dresden · DEMax Planck Institute of Molecular Cell Biology and Genetics · DEUniversity Hospital Schleswig-Holstein · DEHumboldt-Universität zu Berlin · DEUniversity Hospital Leipzig · DEUniversity Hospital of Zurich · CHDeutsches Diabetes-Zentrum e.V. · DEGerman Cancer Research Center · DELeibniz Institute on Aging - Fritz Lipmann Institute (FLI) · DEParacelsus Medical University · ATUniversity of Rostock · DEUniversity of Salzburg · AT
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe rs641738C>T variant located near the membrane-bound O-acyltransferase domain containing 7 (MBOAT7) locus is associated with fibrosis in liver diseases, including non-alcoholic fatty liver disease (NAFLD), alcohol-related liver disease, hepatitis B and C. We aim to understand the mechanism by which the rs641738C>T variant contributes to pathogenesis of NAFLD.
designMice with hepatocyte-specific deletion of MBOAT7 (Mboat7
resultsAllelic imbalance analysis of heterozygous human liver samples pointed to lower expression of the MBOAT7 transcript on the rs641738C>T haplotype. Mboat7
conclusionMboat7 deficiency in mice and human points to an inflammation-independent pathway of liver fibrosis that may be mediated by lipid signalling and a potentially targetable treatment option in NAFLD.
Indexed as
AcyltransferasesAdultAgedAnimalsBiopsyDisease Models, AnimalDisease ProgressionFemaleGenotypeHaplotypesHumansInflammationLiver CirrhosisMaleMembrane ProteinsMiceAcyltransferasesMBOAT7 protein, humanMboat7 protein, mouseMembrane Proteinsliver fibrosis, lipidomicsNAFLDNASH
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.